David Francisco - Feb 15, 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Chief Financial Officer
Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
Feb 15, 2022
Transactions value $
-$22,479
Form type
4
Date filed
2/17/2022, 05:51 PM
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Award $0 +40.3K +246.61% $0.00 56.7K Feb 15, 2022 Direct F1
transaction ORGO Class A Common Stock Tax liability -$15.1K -1.88K -3.31% $8.03 54.8K Feb 15, 2022 Direct
transaction ORGO Class A Common Stock Tax liability -$7.41K -953 -1.74% $7.78 53.9K Feb 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Award $0 +95.7K $0.00 95.7K Feb 15, 2022 Class A Common Stock 95.7K $8.03 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022.
F2 The option becomes exercisable in equal annual installments over four years beginning February 15, 2022.